Tranexamic acid in pertrochanteric fractures: a retrospective analysis of perioperative outcomes after fixation with a proximal femoral nail

John Hanke\textsuperscript{1}, Thomas Mendel\textsuperscript{1}, Matthias Wingert\textsuperscript{2}, Philipp Schenk\textsuperscript{3}, Markus Heinecke\textsuperscript{1} and Arne Wilharm\textsuperscript{2}\textsuperscript{*}

Abstract

Background: Treatment of pertrochanteric femoral fractures is often associated with significant blood loss. It has already been demonstrated that the administration of tranexamic acid (TXA) for endoprosthetic procedures reduces blood losses and leads to a decreased frequency of postoperative complications. The aim of this study is to demonstrate whether the administration of TXA as part of osteosynthesis treatment for pertrochanteric fractures using a proximal femoral nail reduces perioperative blood losses and haemorrhage-related complications.

Methods: In a two-centre retrospective cohort study, 1 g TXA i.v. was administered preoperatively to 294 patients who had suffered from pertrochanteric femoral fractures. The subjects were compared clinically to a historical control group who did not receive TXA (nonTXA). Outcomes were evaluated on the basis of perioperative blood loss, transfusion requirement, and occurrence of complications.

Results: The TXA group showed evidence of a reduction in blood loss (TXA $= 0.97 \pm 0.47$ l; nonTXA $= 1.06 \pm 0.47$ l; $p = 0.004$) and a lower frequency of transfusion (TXA $= 20$%; nonTXA $= 31$%; $p = 0.032$) as compared to the nonTXA group. However, evidence of this therapeutic effect could only be demonstrated at one of the centres on subgroup comparison between the two centres. At the second centre, the data did not show a significant difference. A trend could be seen towards a reduction in postoperative renal failure. No complications occurred resulting from the administration of tranexamic acid.

Conclusion: Preoperative administration of TXA does not lead to an increased rate of thromboembolic complications when applied for treatment of pertrochanteric femoral fractures. Evidence of a positive effect could be seen in principle in relation to the reduction in perioperative blood loss and the frequency of transfusion. The difference in effect between the two centres remains to be clarified: for this reason, it is possible to assume that further factors influencing the efficacy of TXA administration are at play which were not taken into account in this study.

Keywords: Tranexamic acid, Proximal femoral fracture, Haemoglobin monitoring, Geriatric, Proximal femur nail

\textsuperscript{1}John Hanke and Thomas Mendel share the first authorship.

\textsuperscript{*}Correspondence: Arne.Wilharm@med.uni-jena.de

\textsuperscript{2}Department of Trauma-, Hand- and Reconstructive Surgery, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany

Full list of author information is available at the end of the article

Background

Pertrochanteric femoral fractures are the second most common geriatric fractures in Germany in people over 70 years of age, with an annual incidence of 486 per 100,000 inhabitants, second only to medial neck-of-femur
fractures [1]. They not only pose a significant risk to the patients affected in terms of their independence to carry out activities of daily living [2], but can also be life-threatening. For example, the 1-year mortality rate following hip fractures is almost 30% [3].

Approximately 82% of hip-joint fractures treated in Germany with an osteosynthesis approach are now stabilised using an intramedullary nail [4]. In addition to the fracture event itself, both the surgical procedure and any associated blood loss represent a significant burden for elderly patients, who tend to have multiple morbidities. From the literature, rates of perioperative transfusion requirement range from 30% to 84.6% depending on the type of fracture and level of invasiveness [5–9]. These data from the literature indicate a mean blood loss of up to 2100 ml [9]. Blood loss in cases of intracapsular fracture is lower than in extracapsular fracture cases [10].

Postoperative anaemia following treatment of hip fractures leads to greater difficulties in mobilising the patient, increased duration of in-patient treatment, and increased mortality [11, 12]. It should also be noted that blood transfusions can also increase postoperative mortality and morbidity [13]. Due to immune system impairment, the incidence of wound infections and cardiac complications increases, resulting in rising treatment costs [14–16].

In this respect, preventive efforts are aimed at minimising perioperative blood loss. A promising approach can be seen in the use of tranexamic acid (TXA). TXA is a cost-effective synthetic derivative of the amino acid lysine: it binds reversibly to plasminogen to produce an anti-fibrinolytic effect [17]. It has been used since 1966 in various different forms for the treatment of bleeding. Today, TXA is used as part of standard care for elective hip replacement procedures in many hospitals. It has been demonstrated that its use has led to a significant reduction in blood transfusion requirement as well as frequency of renal failure with no increase in complications [18, 19]. Similar results have also been obtained in the area of spinal surgery [20].

From the literature, the first indications can be seen of a similar positive effect of TXA used in the treatment of proximal femoral fractures. For example, Sadegi et al. (2007) saw a reduction in measured blood loss from an average of 1,484 ml to 960 ml due to administration of TXA in patients receiving treatment for hip fractures [5]. A problematic aspect of previous studies was that the number of cases tended to be small. Additionally, different osteosynthesis approaches, and in some cases even endoprosthesis treatments, were included in the studies [5, 21, 22]. In 2016, Farrow et al. published an initial meta-analysis of the available literature, whereby only five publications could be included [23]. The diversity of the studies with regard to the fracture types and surgical treatment approaches included (indeed, these were not even indicated for all studies), makes it difficult to carry out a direct comparison. Particularly striking was the inclusion of some cases with protracted operating times of over 2 h [5, 9, 21, 22, 24, 25].

In summary, Farrow et al. concluded, with a moderate level of evidence, that the administration of TXA reduced the amount of blood transfusions required during treatment of hip fractures [23].

**Study objectives**
The aim of this study is to determine, on the basis of a homogeneous study population, whether preoperative intravenous (i.v.) administration of TXA as part of treatment of pertrochanteric femoral fractures with an intramedullary nail can lead to a reduction in blood loss and frequency of transfusion. The secondary objective of the study is to determine whether the incidence of postoperative complications, such as acute kidney failure, heart attack and death, as well as duration of postoperative admission decreases following administration of TXA. Furthermore, the frequency of TXA-associated complications (thrombosis, embolism, stroke, seizures) is to be recorded.

**Methods**

**Study design**
Based on the positive results obtained in the field of elective hip and knee replacements [19, 26], preoperative i.v. administration of TXA has been applied since 2016 as part of surgical treatment for pertrochanteric femoral fractures with an intramedullary nail at two level-1 trauma centres in accordance with the internal standard operating procedure (SOP). In a two-centre retrospective case–control study, the cohorts of one group of TXA patients (TXA group) in each of the two hospitals were compared to one consecutive group of patients respectively whose surgical treatment took place prior to 2016, i.e. before the introduction of the SOP for preoperative TXA administration (nonTXA group). To ensure better comparability, these groups only included patients who had no contraindications for administration of TXA.

Following recommendations from the literature [25], in the TXA group of each hospital respectively the standard dose of 1 g TXA i.v. was administered 10 min preoperatively once any contraindications had been ruled out and with doses adjusted according to the specialist guidelines in any cases of renal insufficiency (Table 1). Presentation of a pertrochanteric femoral fracture of types 31-A1 to A3 according to the AO classification was defined as the primary inclusion criterion (Fig. 1). Both minimally-invasive and open surgical approaches were included in the
Hanke et al. BMC Musculoskeletal Disorders (2022) 23:950

Analysis. Presentations with any further musculoskeletal injuries were excluded. In addition, those patients having taken any anticoagulant other than acetylsalicylic acid were excluded. Patients in the TXA group were operated on between 11/2016 and 12/2019. The nonTXA group received treatment between 9/2015 and 10/2016.

Data Collection
Through analysis of the digital medical records, it was possible to record the following data for all patients: demographic data (gender, age, weight, height, body mass index (BMI), aspirin intake, fracture type, ASA score); process parameters (surgical technique, knife-to-skin time, drainage system, duration of postoperative admission); and complications (thrombosis, embolism, stroke, heart attack, seizure, death, other); laboratory data from the day of admission (haemoglobin (Hb), haematocrit (Hct), platelet count, creatinine (Crea), glomerular filtration rate (GFR), quick time, activated partial thromboplastin time (aPTT); and from 1st postoperative day (Hb, Hct, platelet count); as well as the lowest GFR or highest creatinine values recorded over the course of treatment. Furthermore, all instances of administration of red cell concentrate (RCC) were recorded.

Preoperative blood volume could be determined by applying the formula devised by Nadler et al. [27], and blood loss determined following the method of Good et al. [28].

Statistical Analysis
Firstly, analysis was performed for each site separately (Clinic 1: University Hospital Jena and Clinic 2: BG Klinikum Bergmannstrost Halle) as well as across both locations (overall) to determine whether there were differences between the patient groups with respect to the demographic data, fracture morphology (AO classification) and the duration of the preoperative in-patient admission. For this purpose, a Chi² test and multivariate analysis of variance (MANOVA) were applied.

In addition, MANOVA was used to test whether there were significant differences in the laboratory parameters recorded between the patient groups preoperatively.

The effects of administration of TXA on the primary outcome parameters of blood loss and need for RCC administration were analysed using Chi² and U tests.

With respect to the secondary outcome parameters, the duration of postoperative in-patient admission and frequency of renal failure and death were compared using a Chi² test.

SPSS V.26 (IBM SPSS Statistics for Windows. Armonk, NY: IBM Corp.) was used for the statistical analysis. The threshold for significance was set at $p = 0.05$.

Results
Two hundred ninety-four patients across two sites (Clinic 1: $N=138$, Clinic 2: $N=156$) were included in the study. On average, the patients (79 men, 215 women) were 81 ± 11 years old. The BMI averaged 26 ± 5 kg/m². On average, the surgical treatment was provided 0.6 days following admission. No differences could be identified between either the TXA and nonTXA group, nor between the sites, with respect to these parameters (Table 2).
Table 2 Preoperative parameters, description of the study population and their mean values, standard deviations (mean ± SD) as well as minimum and maximum values (range). The values are presented both overall across groups as well as separately for patients treated with and without tranexamic acid (TXA) and for the two centres. The p-value (P) with respect to the differences between the two patient groups (nonTXA and TXA) and between the two centres (location) is listed accordingly.

| Parameter                        | Clinic 1 total | Clinic 1 nonTXA | Clinic 1 TXA | p-value | Clinic 2 total | Clinic 2 nonTXA | Clinic 2 TXA | p-value | Clinic 2 location | p-value |
|----------------------------------|----------------|----------------|--------------|---------|----------------|----------------|--------------|---------|-------------------|---------|
| Sex, n (%)                       | 0.599          | 0.442          | 0.104        | 1.000   |                |                |              |         |                   |         |
| Male                             | 79 (27)        | 42 (29)        | 37 (25)      |         | 42 (27)        | 26 (33)        | 16 (21)      |         | 114 (73)          | 52 (67) |
| Female                           | 215 (73)       | 105 (71)       | 110 (75)     |         | 53 (77)        | 48 (70)        |             |         | 52 (67)           | 62 (79) |
| Age, y                           | 0.543          | 0.846          | 0.293        | 0.337   | 0.846          | 0.293          | 0.337        |         | 0.293             | 0.337   |
| Mean (SD)                        | 81 ± 11        | 81 ± 11        | 81 ± 12      |         | 80 ± 11        | 81 ± 11        | 80 ± 10      |         | 82 ± 12           | 81 ± 11 |
| Range                            | 33–102         | 48–97          | 33–102       |         | 42–95          | 51–96          | 42–95        |         | 33–102            | 48–97   |
| Body weight, kg                  | 0.823          | 0.996          | 0.749        | 0.380   | 0.749          | 0.380          |             |         |                   |         |
| Mean (SD)                        | 69 ± 15        | 69 ± 15        | 69 ± 16      |         | 70 ± 15        | 70 ± 13        | 70 ± 17      |         | 69 ± 15           | 68 ± 17 |
| Range                            | 38–118         | 38–115         | 39–118       |         | 45–118         | 46–100         | 45–118       |         | 38–115            | 38–115 |
| Body height, m                   | 0.832          | 0.736          | 0.489        | 0.465   | 0.489          | 0.465          |             |         |                   |         |
| Mean (SD)                        | 1.64 ± 0.09    | 1.65 ± 0.09    | 1.64 ± 0.09  |         | 1.65 ± 0.1    | 1.65 ± 0.09    | 1.65 ± 0.1   |         | 1.64 ± 0.09       | 1.65 ± 0.1 |
| Range                            | 1.44–2.00      | 1.48–1.91      | 1.44–2.00    |         | 1.44–2.00      | 1.48–1.91      | 1.44–2.00    |         | 1.47–1.90         | 1.48–1.86 |
| BMI, kg/m²                       | 0.706          | 0.653          | 0.342        | 0.631   | 0.342          | 0.631          |             |         |                   |         |
| Mean (SD)                        | 26 ± 5         | 25 ± 5         | 26 ± 5       |         | 26 ± 5         | 26 ± 4         | 26 ± 5       |         | 25 ± 5            | 25 ± 5  |
| Range                            | 15–40          | 15–38          | 16–40        |         | 18–38          | 19–38          | 18–36        |         | 15–40             | 15–38   |
| ASS, n (%)                       | 0.715          | 1.000          |             |         | 0.745          | 0.020          |             |         |                   |         |
| Yes                              | 104 (35)       | 50 (34)        | 54 (37)      |         | 39 (28)        | 19 (27)        | 20 (29)      |         | 65 (42)           | 31 (40) |
| No                               | 190 (65)       | 97 (66)        | 93 (63)      |         | 99 (72)        | 50 (73)        | 49 (71)      |         | 91 (58)           | 47 (60) |
| AO classification, n (%)         | 0.785          | 0.975          |             |         | 0.708          | 0.002          |             |         |                   |         |
| A1                               | 111 (38)       | 55 (37)        | 56 (38)      |         | 60 (44)        | 29 (42)        | 31 (45)      |         | 51 (33)           | 26 (33) |
| A2                               | 125 (43)       | 65 (44)        | 60 (41)      |         | 44 (31)        | 23 (33)        | 21 (30)      |         | 81 (52)           | 42 (54) |
| A3                               | 58 (20)        | 27 (18)        | 31 (21)      |         | 34 (25)        | 17 (25)        | 17 (25)      |         | 24 (15)           | 10 (13) |
| ASA                              | 0.441          | 0.759          |             |         | 0.405          | 0.004          |             |         |                   |         |
| Mean (SD)                        | 2.7 ± 0.5      | 2.8 ± 0.5      | 2.7 ± 0.6    |         | 2.6 ± 0.6      | 2.7 ± 0.5      | 2.6 ± 06     |         | 2.8 ± 0.5         | 2.9 ± 0.4 |
| Range                            | 1–4            | 2–4            | 1–4          |         | 1–4            | 2–4            | 1–4          |         | 1–4               | 2–4     |
| Hb, mmol/l                       | 0.002          | 0.153          |             |         | 0.004          | 0.319          |             |         |                   |         |
| Mean (SD)                        | 7.83 ± 0.98    | 8.01 ± 0.98    | 7.66 ± 0.95  |         | 7.89 ± 0.93    | 8 ± 0.93       | 7.78 ± 0.92  |         | 7.78 ± 1.02       | 8.01 ± 1.02 |
| Range                            | 45–105         | 45–105         | 51–97        |         | 55–103         | 06.100203      | 55–9.7      |         | 4.5–105           | 4.5–105 |
| HK, %                            | < 0.001        | 0.040          |             |         | 0.003          | 0.473          |             |         |                   |         |
| Mean (SD)                        | 0.038 ± 0.05   | 0.39 ± 0.05    | 0.37 ± 0.05  |         | 0.38 ± 0.04    | 0.39 ± 0.04    | 0.37 ± 004   |         | 0.38 ± 0.05       | 0.39 ± 0.05 |
| Range                            | 0.22–0.51      | 0.22–0.51      | 0.25–047     |         | 0.26–0.49      | 0.29–049       | 0.26–047     |         | 0.22–0.51         | 0.22–0.51 |
Table 2 (continued)

|                      | overall |             | Clinic 1 |             | Clinic 2 | location |
|----------------------|---------|-------------|----------|-------------|----------|----------|
|                      | total   | nonTXA      | TXA      | p-value     | total    | nonTXA   | TXA      | p-value | total    | nonTXA   | TXA      | p-value |
| pre-surgery stay, (d)| (N=294) | (N=147)     | (N=147)  | p-value     | (N=138)  | (N=69)   | (N=69)   | p-value | (N=156)  | (N=78)   | (N=78)   | p-value |
| Mean (SD)            | 0.6±0.7 | 0.7±0.8     | 0.5±0.7  | 0.249       | 0.6±0.8  | 0.6±0.9  | 0.6±0.6  | 0.591   | 0.6±0.7  | 0.7±0.7  | 0.5±0.7  | 0.253   |
| Range                | 0–7     | 0–7         | 0–2      | 0–7         | 0–7      | 0–2      | 0–3      | 0–3     | 0–2      |
Patients from Clinic 2 had a slightly higher ASA score on average (Clinic 1: 2.6±0.6, Clinic 2: 2.8±0.5; p=0.004) and took aspirin more frequently (Clinic 1: 28%, Clinic 2: 42%; p=0.020). However, there were no significant differences for these parameters between the study groups at the respective sites (Table 2).

Preoperatively, the TXA group in Clinic 2 had a lower Hb, and at both sites this group had a lower Hct value than the nonTXA group, such that these laboratory values showed differences across the two groups preoperatively (preOP Hb: NonTXA 8.01±0.98, TXA 7.66±0.95; p=0.002; preOP Hct: NonTXA 0.39±0.05, TXA 0.37±0.05, p<0.001) (Table 2).

The majority of the fractures treated were A2 fractures (43%), followed by A1 fractures (38%) and A3 fractures (20%) (Table 2).

Surgical stabilisation using an intramedullary nail was carried out in 254 patients (86%) using a closed (CRIF) approach, and in 40 patients (14%) through open reduction and internal fixation (ORIF) (Table 3). The knife-to-skin times between the nonTXA and TXA groups only differed in Clinic 2 between the nonTXA and the TXA groups treated with CRIF, by an average of 8 min. There were no significant differences between the sites in this respect (Table 3).

At both sites, TXA was administered to 50% of patients treated using CRIF and ORIF (Table 3).

Administration of TXA in Clinic 1 led to a significant reduction in blood loss in both the open (non TXA 1.25±0.36 l, TXA 1.02±0.34 l; p = 0.034) and the percutaneous (nonTXA 0.97±0.47 l, TXA 0.79±0.39 l; p = 0.001) approaches; whilst blood loss in Clinic 2 showed no differences between TXA and nonTXA groups (ORIF: nonTXA 1.64±0.45 l, TXA 1.30±0.50 l; p = 0.499; CRIF: nonTXA 1.06±0.42; TXA 1.06±0.50 l; p = 0.567). However, the reduction in blood loss was so pronounced in Clinic 1 that a significant reduction in blood loss was also seen when taking an overall view both for patients treated with CRIF (nonTXA 1.01±0.44 l, TXA 0.94±0.47 l; p = 0.06) and for all patients (nonTXA 1.06±0.47 l, TXA 0.97±0.47 l; p = 0.004) (Table 4, Fig. 2).

The proportion of patients who received a blood transfusion following surgery was significantly lower in the TXA group (nonTXA = 31%, TXA = 20%; p = 0.032) (Table 4). This difference can also be largely attributed to the patients in Clinic 1, where 39% of the nonTXA patients were transfused, falling to 10% for the TXA group (p = <0.001). In Clinic 2, on the other hand, no reduction in the frequency of transfusion could be identified (Table 4).

Twenty patients suffered from postoperative (postOP) kidney failure, whereby the majority of these patients underwent surgery in Clinic 1 (postOP kidney failure: Clinic 1 N=18, Clinic 2 N=2; p < 0.001). In the TXA group, the incidence was 4%, whilst 10% of patients in the nonTXA group suffered from postoperative renal failure. A significant difference could not be demonstrated here due to the small number of cases (Table 5). No further complications occurred in either centre.

The duration of postoperative admission was not significantly influenced by administration of TXA (p = 0.056) when both centres are considered together (Table 5). However, it appears that the CRIF patients in Clinic 1 who received TXA had significantly shorter postoperative admissions at the centre (postOP admission: NonTXA = 9±4d, TXA = 8±3, p = 0.039).

No complications which could be related to administration of TXA occurred. No thrombo-embolic events or seizures were observed. In the TXA group, one patient died of aspiration pneumonia. In the control group, two elderly patients experienced a continued deterioration in their general condition, which resulted in death due to multiple organ failure.

Discussion

TXA can reduce blood loss and need for transfusion in the context of orthopaedic surgery by reversibly blocking fibrinolysis: it is therefore recommended for endoprosthetic treatments as part of the American guidelines [29]. However, by 2020 there were only 11 high-quality studies on the treatment of pertrochanteric fractures, in which TXA was used in 596 patients. These studies were summarised as part of a meta-analysis by Yu [30]. There were only 6 studies, with a total of 261 patients, in which patients were administered TXA and osteosynthesis was carried out using an intramedullary nail. Yu concluded that TXA is safe and effective, but further studies with larger sample sizes are needed. Scientific interest around the globe in reducing blood loss in cases of hip fracture by administering TXA can be seen reflected in the fact that in 2021 there were a further 38 reviews and original articles on Medline on the use of TXA in the treatment of hip fractures.

In this retrospective study, we were able to include 147 patients who received TXA preoperatively as part of treatment for a pertrochanteric femoral fracture using an intramedullary nail. Both significantly lower blood loss and a reduction in the rate of transfusions could be demonstrated. It is striking that this effect can only be identified in one of the two study sites. Whilst in Clinic 1 a significant effect of TXA on blood loss and transfusion frequency could be demonstrated, no significant differences were observed in any of the measured parameters in Clinic 2. To what extent this is due to the slightly higher ASA score and the more
Table 3  Intraoperative parameters, surgical approach and knife-to-skin time, mean values, standard deviations (mean± SD) as well as minimum and maximum values (range). The values are presented both overall across groups as well as separately for patients treated with and without tranexamic acid (TXA) and for the two centres. The p-value (P) is with respect to the differences between the two patient groups (nonTXA and TXA) and between the two centres (location) is listed accordingly.

|                        | overall total (N = 294) | nonTXA (N = 147) | TXA (N = 147) | p-value | Clinic 1 total (N = 138) | nonTXA (N = 69) | TXA (N = 69) | p-value | Clinic 2 total (N = 156) | nonTXA (N = 78) | TXA (N = 78) | p-value | Location total p-value |
|------------------------|-------------------------|------------------|---------------|---------|-------------------------|------------------|---------------|---------|-------------------------|------------------|---------------|---------|------------------------|
| Surgery technique, n (%) | 1.000                    |                  |               |         | 1.000                   |                  |               |         | 1.000                   |                  |               |         | 0.308                  |
| ORIF                   | 40 (14)                 | 20 (14)          | 20 (14)       |         | 22 (16)                | 11 (16)          | 11 (16)       |         | 18 (12)                | 9 (12)           | 9 (12)        |         |                       |
| CRIF                   | 254 (86)                | 127 (86)         | 127 (86)      |         | 116 (84)               | 58 (84)          | 58 (84)       |         | 138 (88)               | 69 (88)          | 69 (88)       |         |                       |
| Cut suture time, (min) | 0.649                   |                  |               |         | 0.082                   |                  |               |         | 0.252                   |                  |               |         | 0.655                  |
| Mean (SD)              | 60 ± 32                 | 60 ± 34          | 61 ± 30       | 0.066   | 61 ± 34                | 66 ± 37          | 56 ± 30       | 0.025   | 59 ± 31                | 56 ± 32          | 62 ± 29        | 0.702   |                       |
| Range                  | 18–225                  | 18–225           | 21–165        |         | 18–185                 | 18–185           | 21–155        |         | 20–225                 | 20–225           | 23–140         |         |                       |
| ORIF                   | 0.111                   |                  |               |         | 0.066                   |                  |               |         | 0.677                   |                  |               |         | 0.981                  |
| Mean (SD)              | 110 ± 42                | 122 ± 47         | 100 ± 35      |         | 111 ± 40               | 126 ± 41         | 95 ± 34       |         | 111 ± 46               | 116 ± 55         | 106 ± 37       |         |                       |
| Range                  | 31–225                  | 41–225           | 31–155        |         | 42–185                 | 74–185           | 42–155        |         | 31–225                 | 41–225           | 31–140         |         |                       |
| CRIF                   | 0.605                   |                  |               |         | 0.149                   |                  |               |         | 0.025                   |                  |               |         | 0.702                  |
| Mean (SD)              | 52 ± 21                 | 51 ± 20          | 52 ± 23       |         | 51 ± 22                | 54 ± 22          | 48 ± 23       |         | 52 ± 20                | 48 ± 17          | 56 ± 22        |         |                       |
| Range                  | 18–130                  | 18–112           | 21–130        |         | 18–123                 | 18–112           | 21–123        |         | 20–130                 | 20–101           | 23–130         |         |                       |
|                      | overall | Clinic 1 | Clinic 2 | Location |
|----------------------|---------|----------|----------|----------|
|                      | total   | nonTXA   | TXA      | total    | nonTXA   | TXA      | total    | nonTXA   | TXA      | p-value   |
|                      | (N=294) | (N=147)  | (N=147)  | (N=138)  | (N=69)   | (N=69)   | (N=156)  | (N=78)   | (N=78)   | p-value   |
|                      |         |          |          |          |          |          |         |          |          |          |
| RCC volume, (l)      |         |          |          |          |          |          |          |          |          |          |
| Mean (SD)            | 0.012   | <0.001   |          |          |          |          |          |          |          |          |
| Range                | 0.05    |          |          |          |          |          |          |          |          |          |
| ORIF                 | 0.250   | 0.066    |          |          |          |          |          |          |          |          |
| Mean (SD)            | 0.023   | <0.001   |          |          |          |          |          |          |          |          |
| Range                | 0.007   |          |          |          |          |          |          |          |          |          |
| RCC, n (%)           | 0.032   | <0.001   |          |          |          |          |          |          |          |          |
| Yes                  | 75 (25) | 46 (31)  | 29 (20)  | 34 (25)  | 27 (39)  | 7 (10)   | 41 (26)  | 19 (24)  | 22 (28)  | 0.716    |
| No                   | 219 (75)| 101 (69)| 118 (80)| 104 (75)| 42 (61)  | 62 (90)  | 115 (74)| 59 (76)  | 56 (72)  | 0.789    |
| CRIF                 | 0.100   | 0.001    |          |          |          |          |          |          |          |          |
| Yes                  | 58 (23) | 35 (28)  | 23 (18)  | 23 (20)  | 19 (33)  | 4 (7)    | 35 (25)  | 16 (23)  | 19 (28)  | 0.696    |
| No                   | 196 (77)| 92 (72)  | 104 (82)| 93 (80)  | 39 (67)  | 54 (93)  | 103 (75)| 53 (77)  | 50 (72)  | 0.686    |
| Blood loss (BL), (l) | 0.004   | <0.001   |          |          |          |          |          |          |          |          |
| Mean (SD)            | 1.01±0.47| 1.06±0.47| 0.97±0.47| 0.92±0.43| 1.02±0.46| 0.83±0.39| 1.09±0.48| 1.10±0.47| 1.09±0.50| 0.766    |
| Range                | 0.00–2.68| 0.15–2.68| 0.00–2.10| 0.00–2.31| 0.15–2.31| 0.00–1.96| 0.07–2.68| 0.21–2.68| 0.07–2.10| 0.924    |
| ORIF                 | 0.246   | 0.034    |          |          |          |          |          |          |          | 0.879    |
| Mean (SD)            | 1.29±0.45| 1.42±0.44| 1.14±0.43| 1.14±0.36| 1.25±0.36| 1.02±0.34| 1.47±0.49| 1.64±0.45| 1.30±0.50|          |
| Range                | 0.39–2.43| 0.62–2.43| 0.39–2.10| 0.39–1.76| 0.62–1.76| 0.39–1.51| 0.54–2.43| 0.92–2.43| 0.54–2.10|          |
| CRIF                 | 0.006   | 0.001    |          |          |          |          |          |          |          | 0.616    |
| Mean (SD)            | 0.97±0.46| 1.01±0.44| 0.94±0.47| 0.88±0.44| 0.97±0.47| 0.79±0.39| 1.05±0.46| 1.03±0.42| 1.06±0.50|          |
| Range                | 0.00–2.68| 0.15–2.68| 0.00–1.99| 0.00–2.31| 0.15–2.31| 0.00–1.96| 0.07–2.68| 0.21–2.68| 0.07–1.99|          |
frequent use of aspirin cannot be determined with any certainty. Whether the use of aspirin during elective total hip or knee replacement leads to increased blood loss or greater postoperative bleeding has been investigated in several studies, and no differences have been found [31, 32]. Very disparate data can be found in the literature with respect to perioperative blood loss. For example, Tengberg et al. report blood loss at 2100.4 ml without TXA [9], whilst Chen calculate it at 616.4 ml [33]. However, blood loss where there was no administration of TXA did not differ between our two study centres and can be regarded as moderate compared to other studies (blood loss: Clinic 1 = 1.02 ± 0.46 l, Clinic 2 = 1.10 ± 0.47 l; p = 0.924). The patient populations of the two centres were also very similar and were distributed in a homogeneous manner, particularly within each centre. In addition, the same surgical procedure was used and the same guidelines for transfusion were followed with respect to the indication for transfusion [34]. Both clinical sites are under the same medical management and operate two-way exchanges of surgeons for the purpose of standardising surgical procedures (amongst other things), such that differences in treatment of pertrochanteric fractures between the two centres cannot be assumed to be a cause. There are only a few studies in the literature in which TXA does not lead to a reduction in perioperative blood loss. In contrast with the results from most other studies, Virani et al. were not able to identify a reduction in blood loss when applying TXA topically [35]. The cause for this remains unclear, as can also be said for our study. It is clear to see that there are factors which have not yet been identified that have an effect on the efficacy of TXA and which have not been sufficiently characterised in clinical trials.

Compared to other studies, the transfusion rate without TXA was relatively low at 31%. In this regard, Schiavone et al. 2018 investigated the treatment of pertrochanteric fractures with an intramedullary nail, and were able to reduce the transfusion rate with administration of TXA from 60.46% to 42.55% [36], i.e. even with TXA, the transfusion rate was still 11.55% higher than in our study without TXA. One of the reasons for this could be that many studies have reported a significantly lower threshold for a transfusion protocol to be triggered than is the norm in Germany. Similarly high transfusion rates were reported by Lei et al (2017), who transfused 56.09% of patients without TXA and 28.20% of patients receiving TXA [37]. With TXA, the transfusion rate in our study was a mere 20%; and in Clinic 1 it was even lower at 10%. As such, the study was able to demonstrate that even with a transfusion rate that is initially relatively low, a further reduction can be achieved through administration of TXA.

Despite both centres operating according to the cross-sectional haemotherapy guidelines from 2014 [34], there is the possibility of bias occurring when evaluating the transfusion rates due to the different assessments of the relative threshold triggers for transfusion as made by the treating physicians.

With respect to trauma patients, the CRASH II study was able to show that the shorter the time delay from...
Table 5 Postoperative parameters, mean values, standard deviations (mean±SD) and minimum and maximum values (range). The values are presented both overall across groups as well as separately for patients treated with and without tranexamic acid (TXA) and for the two centres. The p-value (P) is with respect to the differences between the two patient groups (nonTXA and TXA) and between the two centres (location) is listed accordingly.

|                     | overall total (N = 294) | nonTXA (N = 147) | TXA (N = 147) | p-value | Clinic 1 total (N = 138) | nonTXA (N = 69) | TXA (N = 69) | p-value | Clinic 2 total (N = 156) | nonTXA (N = 78) | TXA (N = 78) | p-value | Location total | p-value |
|---------------------|-------------------------|------------------|---------------|---------|-------------------------|----------------|---------------|---------|-------------------------|----------------|---------------|---------|---------------|---------|
| Post-surgery stay, (d) |                         |                  |               |         |                         |                  |               |         |                         |                  |               |         |               |         |
| Mean (SD)           | 9 ± 3                   | 9 ± 4            | 8 ± 3         | 0.056   | 9 ± 4                   | 9 ± 4           | 8 ± 3         | 0.007   | 9 ± 3                   | 9 ± 3           | 9 ± 3         | 0.749   | 0.222         |         |
| Range               | 3–27                    | 3–27             | 3–16          |          | 3–27                    | 3–27            | 3–16          |          | 3–17                    | 4–17            | 3–16          |          |               |         |
| ORIF                |                         |                  |               |         |                         |                  |               |         |                         |                  |               |         |               |         |
| Mean (SD)           | 9 ± 3                   | 10 ± 4           | 9 ± 3         | 0.172   | 9 ± 4                   | 11 ± 4          | 8 ± 3         | 0.062   | 10 ± 2                  | 9 ± 2           | 10 ± 2        | 0.441   | 0.900         |         |
| Range               | 4–23                    | 9–23             | 4–15          |          | 4–23                    | 7–23            | 4–15          |          | 6–13                    | 6–13            | 7–12          |          |               |         |
| CRIF                |                         |                  |               |         |                         |                  |               |         |                         |                  |               |         |               |         |
| Mean (SD)           | 9 ± 3                   | 9 ± 4            | 8 ± 3         | 0.133   | 8 ± 4                   | 9 ± 4           | 8 ± 3         | 0.039   | 9 ± 3                   | 9 ± 3           | 9 ± 3         | 0.904   | 0.175         |         |
| Range               | 3–27                    | 3–27             | 3–16          |          | 3–27                    | 3–27            | 3–16          |          | 3–17                    | 4–17            | 3–16          |          |               |         |
| Renal failure, n (%)|                         |                  |               |         |                         |                  |               |         |                         |                  |               |         |               |         |
| Yes                 | 20 (7)                  | 14 (10)          | 6 (4)         | 0.103   | 18 (13)                 | 13 (19)         | 5 (7)         | 0.075   | 2 (1)                   | 1 (1)           | 1 (1)         | 1.000   | <0.001        |         |
| No                  | 274 (93)                | 133 (91)         | 141 (96)      |          | 120 (87)                | 56 (81)         | 64 (93)       |          | 154 (99)                | 77 (99)         | 77 (99)       |          |               |         |
| dead, n (%)         |                         |                  |               |         |                         |                  |               |         |                         |                  |               |         |               | 1.002  |
| Yes                 | 3 (1)                   | 2 (1)            | 1 (1)         |          | 3 (2)                   | 2 (3)           | 1 (1)         |          |                         |                  |               |         |               |         |
| No                  | 291 (99)                | 145 (99)         | 146 (1)       |          | 135 (98)                | 67 (97)         | 68 (99)       |          | 156 (100)               | 78 (100)        | 78 (100)      |          |               |         |
trauma to administration, the greater the effectiveness of TXA [38]. For elective surgeries, TXA is given just before the start of surgery and any blood losses only occur either during the operation or after the operation. Studies with large sample sizes were able to show evidence of a benefit for patients undergoing elective procedures for endoprosthesis [18]. In the case of pertrochanteric fractures, the fracture itself leads to a significant amount of blood loss [39], which was not recorded separately in this study. The effects of tranexamic acid can only be expected to be reflected in the blood loss caused by the surgery and any postoperative blood loss. In this respect, it seems logical that improved effects would be seen in interventions involving higher blood losses, such as ORIF for pertrochanteric femoral fractures, and this could also be shown in this study.

The duration of postoperative admission following treatment of hip fractures is determined primarily on the basis of availability of geriatric rehabilitation beds and beds in short-term care facilities, with a lesser role played by actual medical grounds. In this respect, this variable should be interpreted with caution.

Determining the optimal dose of TXA is still problematic. Different dosages and timings for administration of TXA have been described in the literature. For example, a single 1 g dose has been given before surgery [35, 40, 41]; or 10 mg/kg [42] or 15 mg/kg [7, 36, 43, 44] doses have been applied according to body weight. In some cases, a second dose was administered postoperatively [9, 42, 43]. Local application of 2 g or 3 g TXA has also been trialled [35, 45]. In all of the studies cited here, blood loss associated with surgical treatment of hip fractures was reduced, and complications were not seen to increase. However, the number of cases is so small that it is not possible to make recommendations for a therapy regimen. We selected the 1 g dose primarily because it was the easiest to dose and falls within the range stated in the specialist information, which recommends 0.5 to 1 g. The dose was therefore between 10 mg/kg and 15 mg/kg for most patients.

Conclusions
In summary, the administration of TXA prior to surgical treatment of pertrochanteric fractures with an intramedullary nail leads to a significant reduction in blood loss and the number of units of blood required for transfusion. This effect is even more pronounced in cases where higher blood losses are seen in treatment without TXA. Patient’s on aspirin as a pre-existing medication may exhibit a competing effect with the TXA effect. Side effects and increased complication rates, thrombo-embolic events in particular, have not been observed. A trend towards a reduction in the frequency of postoperative renal failure can be seen, but is not significant in this study. Based on positive experiences when implemented in other surgeries with an increased risk of bleeding and based on recommendations from the current literature, routine administration of tranexamic acid as part of treatment of hip fractures should be considered, whereby ideally prospective randomised trials with significantly higher case numbers, or registry studies, would be implemented for further investigation. The effects of accidental administration of TXA on fracture-associated haemorrhage should also be investigated in further studies.

Limitations of the study
The study included patients from two different centres. The inclusion period was relatively protracted: 4 years. However, the statistical evaluation demonstrated that the patient populations were comparable despite this. The transfusion protocol was implemented in both clinics according to the cross-sectional haemotherapy guidelines from 2014 [34], and there were no changes to the protocol over the course of the inclusion period.

This is a retrospective, case–control study (evidence level 3) with a small sample size. The patient groups from both sites differ significantly with respect to frequency of preoperative aspirin intake and ASA score, which places constraints on how we can interpret our data. Nevertheless, the study has provided an indication of the potential significance of the competing effects of ASA and the extent of comorbidities.

Abbreviations
apTT: Activated partial thromboplastin time; BMI: Body mass index; Crea: Creatinine; CRIF: Closed reduction and internal fixation; Fig: Figure; GFR: Glomerular filtration rate; Hb: Haemoglobin; Hct: Haematocrit; i.v.: Intravenous; MANOVA: Multivariate analysis of variance; nonTXA: Group patient group got no tranexamic acid, ORIF: Open reduction and internal fixation, postop: Postoperative; preOP: Preoperative; RCC: Red cell concentrate; SOP: Standard operating procedure; TXA: Tranexamic acid.

Acknowledgements
Not applicable.

Authors’ contributions
Study design, conception, and critical revision: TM, MW, AW. Acquisition of date: JH, MW, AW. Analysis and interpretation of data: PS, JH, TM, AW. Literature search and drafting of manuscript: AW, JH, TM, PS. Final manuscript review/ editing: JH, TM, MW, MH, PS, AW. All authors read and approved the final version of the manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL. There was no funding associated with the development and execution of this research project.
Availability of data and materials
The datasets generated during and analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study is a retrospective analysis of patients with pertrochanteric femur fractures treated surgically between 2016 and 2019 at the University Hospital Jena and BG Klinikum Bergmannstrost Halle, Germany. It was approved by the local ethic committee of the University Hospital Jena (4937–09/16) and has been approved by the independent Medical Ethics Committee of the Medical Council of Saxony-Anhalt, Germany, and confirmed under approval no. 76/19.

Consent for publication
Not applicable.

Competing interests
The authors do not have any conflict of interest or competing interest to report associated with this research.

Author details
1 Department of Trauma and Reconstructive Surgery, BG Klinikum Bergmannstrost Halle gGmbH, Merseburger Strasse 165, 06120 Halle (Saale), Germany. 2 Department of Trauma-, Hand- and Reconstructive Surgery, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany. 

References
1. Rupp M, Walter N, Pfeifer C, Lang S, Kerschbaum M, Krutsch W, et al. The Incidence of Fractures Among the Adult Population of Germany. Dtsch Arztebl Int. 2021;118(40):665–9. https://doi.org/10.3238/arztebl.m2021.0238.
2. Schürch MA, Rizzoli R, Mermillod B, Vasey H, Michel JP, Bonjour JP. A population-based study. BMC Musculoskelet Disord. 2011;12(1):105. https://doi.org/10.1186/1471-2474-12-105.
3. Panula J, Pihlajamäki H, Mattila VM, Jaatinen P, Vahlberg T, Aarnio P, et al. Incidence of Fractures Among the Adult Population of Germany. Dtsch Gesundheitswesen 2020.
4. Fillingham YA, Ramkumar DB, Jevsevar DS, Yates AJ, Bini SA, Clarke HD, et al. Tranexamic acid in total knee replacement: the endorsed clinical practice guides of the American association of hip and knee surgeons, American society of regional anesthesia and pain medicine, American academy of orthopaedic surgeons, hip society, and knee surgeons. J Bone Joint Surg. 2016;98-B(8):747–53. https://doi.org/10.3109/0301-620X.988.36645.
5. Fossa NB, Kehlet H. Hidden blood loss after surgery for hip fracture. J Bone Joint Surg Br. 2006;88-B(8):1053–9. https://doi.org/10.3109/0301-620X.988.17534.
6. Halm EA, Wang JI, Boockvar K, Penodo J, Silberzweig SB, Magaziner J, et al. The Effect of Perioperative Anemia on Clinical and Functional Outcomes in Patients With Hip Fracture. J Orthop Trauma. 2004;18(6):369–74. https://doi.org/10.1097/00005131-200407000-00007.
7. Lawrence VA, Silverstein JH, Cornell JE, Pederson T, Noveck H, Carson JL. Higher Hb level is associated with better early functional recovery after hip fracture repair. Transfusion. 2003;43(2):1717–22. https://doi.org/10.1046/j.1107-1258.2003.00581.x.
8. Oddaert J, Raux M, Khami F, Roux B. Perioperative Management of Elderly Patients With Hip Fracture. Anesthesiology. 2014;121(6):1336–41. https://doi.org/10.1097/ALN.0000000000000478.
9. Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. The Lancet. 2007;370(9585):415–26. https://doi.org/10.1016/S0140-6736(07)61197-0.
10. Carson JL, Terrin ML, Noveck H, Sanders DW, Chairman BR, Rhoads GG, et al. Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery. N Engl J Med. 2011;365(26):2453–62. https://doi.org/10.1056/NEJMoa1102452.
11. Hill GE, Frawley WH, Griffith KE, Forrestner JE, Minei JP. Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. J Trauma. 2003;54(5):908–14. https://doi.org/10.1097/00005131-200305000-00017.
12. Poeran J, Rasul R, Suzuki S, Danningter T, Mazumdar M, Oppener M, et al. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ. 2014;349:g4829.
13. Goldstein M, Feldmann C, Wulf H, Wessmann T. Tranexamic acid prophylaxis in hip and knee joint replacement. Deutsches Aerzteblatt Online. 2017. https://doi.org/10.3238/arztebl.2017.0824.
14. Chenyani T, Maier SP, Bianco K, Slobodyanyuk K, Rattenni RN, Lafage V, et al. Efficacy of tranexamic acid on surgical bleeding in spine surgery: a meta-analysis. Spine J. 2015;15(4):752–61. https://doi.org/10.1016/j.spinee.2015.01.013.
15. Zufferey PJ, Miquet M, Quinet S, Martin P, Adam P, Albaladejo P, et al. Tranexamic acid in hip fracture surgery: a randomized controlled trial. Br J Anaesth. 2010;104(1):23–30. https://doi.org/10.1093/bja/aep314.
16. Vijay BS, Bedi V, Mitra S, Das B. Role of tranexamic acid in reducing post-operative blood loss and transfusion requirement in patients undergoing hip and femoral surgeries. Saudi J Anaesth. 2013;7(1):29–32. https://doi.org/10.4103/1658-354X.109803.
17. Fanow LS, Smith TO, Ashcroft GP, Myint PK. A systematic review of tranexamic acid in hip fracture surgery. Br J Clin Pharmacol. 2016;82(6):1458–70. https://doi.org/10.1111/bcp.13079.
18. Emara WM, Moez KK, Elkholy AH. Topical versus intravenous tranexamic acid as a blood conservation intervention for reduction of post-operative bleeding in hemiarthroplasty. Anesth Essays Res. 2014;8(1):48–53. https://doi.org/10.4103/0259-1162.129808.
19. Lee C, Freeman R, Edmundson M, Rogers BA. The efficacy of tranexamic acid in hip hemiarthroplasty surgery: an observational cohort study. Injury. 2015;46(10):1978–82. https://doi.org/10.1016/j.injury.2015.06.039.
20. Alshydra S, Sarda P, Sukem K, Nargol A, Blenkinsopp J, Mason JM. Tranexamic acid in total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg Br. 2011;93(12):1577–85. https://doi.org/10.1302/0301-620X.98B6.36645.
21. Nadler SB, Hidalgo JH, Bloch T. Prediction of blood volume in normal human adults. Surgery. 1962;51(2):124–32.
22. Good L, Peterson E, Lisander B. Tranexamic acid decreases external blood loss but not hidden blood loss in total knee replacement. Br J Anaesth. 2003;90(5):596–9. https://doi.org/10.1093/bja/aeg111.
23. Fillingham YA, Ramkumar DB, Jevsevar DS, Yates AJ, Bini SA, Clarke HD, et al. Tranexamic acid in total joint arthroplasty: the endorsed clinical practice guides of the American association of hip and knee surgeons, American society of regional anesthesia and pain medicine, American academy of orthopaedic surgeons, hip society, and knee surgeons. J Bone Joint Surg Br. 2017;99(12):1577–85. https://doi.org/10.1302/0301-620X.98B6.36645.
30. Yu X, Wang J, Wang X, Xie L, Chen C, Zheng W. The efficacy and safety of tranexamic acid in the treatment of intertrochanteric fracture: an updated meta-analysis of 11 randomized controlled trials. J Thromb Thrombolysis. 2020. https://doi.org/10.1007/s11239-019-02034-1.

31. Meier R, Marthy R, Saelly CH, Kuster MS, Giesinger K, Rüdli H. Comparison of preoperative continuation and discontinuation of aspirin in patients undergoing total hip or knee arthroplasty. Eur J Orthop Surg Traumatol. 2016;26(8):921–8. https://doi.org/10.1007/s00590-016-1830-7.

32. Schwab P-E, Lavand'Homme P, Yombi J, Thienpoint E. Aspirin monotherapy continuation does not result in more bleeding after knee arthroplasty. Knee Surg Sports Traumatol Arthrosc. 2017;25(8):2586–93. https://doi.org/10.1007/s00167-015-3824-0.

33. Chen F, Jiang Z, Li M, Zhu X. Efficacy and safety of perioperative tranexamic acid in elderly patients undergoing trochanteric fracture surgery: a randomised controlled trial. Hong Kong Med J. 2019;25(2):120–6. https://doi.org/10.12809/hkmj187570.

34. Bundesärztekammer. Querschnitts-Leitlinien (BÄK) zur Therapie mit Blutkomponenten und Plasmaderivaten. 4 überarbeitete und aktualisierte Auflage. 2014.

35. Virani SR, Dahapute AA, Panda I, Bava SS. Role of Local Infiltration of Tranexamic Acid in Reducing Blood Loss in Pentoarthroplasty in the Elderly Population. Malays Orthop J. 2016;10(3):26–30. https://doi.org/10.5704/MOJ.1611.013.

36. Schiavone A, Bisaccia M, Inkov I, Rinonapoli G, Manni M, Rollo G, et al. Tranexamic Acid in Pertoarthroplasty Femoral Fracture: Is it a Safe Drug or Not? Folia Med (Plovdiv). 2018;60(1):67–78. https://doi.org/10.1515/folmed-2017-0070.

37. Lei J, Zhang B, Cong Y, Zhuang Y, Wei X, Fu Y, et al. Tranexamic acid reduces hidden blood loss in the treatment of intertrochanteric fractures with PFNA: a single-center randomized controlled trial. J Orthop Surg Res. 2017;12(1):124. https://doi.org/10.1186/s13018-017-0625-9.

38. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. The Lancet. 2011;377(9771):1096–101.e2. https://doi.org/10.1016/s0140-6736(11)60278-x.

39. Smith GH, Tsang J, Molyneux SG, White TO. The hidden blood loss after hip fracture. Injury. 2011;42(2):133–5. https://doi.org/10.1016/j.injury.2010.02.015.

40. Zhou XD, Zhang Y, Jiang LF, Zhang JJ, Zhou D, Wu LD, et al. Efficacy and Safety of Tranexamic Acid in Intertrochanteric Fractures: A Single-Blind Randomized Controlled Trial. Orthop Surg. 2019;11(6):635–42. https://doi.org/10.1111/os.12511.

41. Lei J, Zhang B, Cong Y, Zhuang Y, Wei X, Fu Y, et al. Tranexamic acid reduces hidden blood loss in the treatment of intertrochanteric fractures with PFNA: a single-center randomized controlled trial. J Orthop Surg Res. 2017;12(1). https://doi.org/10.1186/s13018-017-0625-9.

42. Tian S, Shen Z, Liu Y, Zhang Y, Peng A. The effect of tranexamic acid on hidden bleeding in older intertrochanteric fracture patients treated with PFNA. Injury. 2018;49(3):680–4. https://doi.org/10.1016/j.injury.2018.01.026.

43. Luo X, He S, Lin Z, Li Z, Huang C, Li Q. Efficacy and Safety of Tranexamic Acid for Controlling Bleeding During Surgical Treatment of Intertrochanteric Fragility Fracture with Proximal Femoral Nail Anti-rotation: A Randomized Controlled Trial. Indian J Orthop. 2019;53(2):263–9. https://doi.org/10.4103/ortho.IJOrtho_401_17.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions